Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (11-20 of 755) with videos related to

Pageof 76
Sort By:
Seminars in Arthritis and Rheumatism|July 16, 2008
Serum immunoglobulins and risk of infection: how low can you go?Daniel E Furst
Arthritis and Rheumatism|January 1, 1994
Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugsD E Furst
Clinical and Experimental Rheumatology|May 1, 1997
From disease modification to disease control in rheumatoid arthritisD E Furst
Current Opinion in Rheumatology|May 6, 1998
Update on clinical trials in the rheumatic diseasesD E Furst
British Journal of Rheumatology|December 24, 1997
The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseasesD E Furst
The American Journal of Medicine|January 11, 2000
Pharmacology and efficacy of cyclooxygenase (COX) inhibitorsD E Furst
Clinical and Experimental Rheumatology|March 20, 1999
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritisD E Furst
Seminars in Arthritis and Rheumatism|October 1, 1993
Comparing the strengths and weaknesses of observational and experimental studies using a postmarketing surveillance study as a protypic exampleD E Furst
Lupus|June 1, 1996
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseasesD E Furst
Seminars in Arthritis and Rheumatism|January 2, 2009
The risk of infections with biologic therapies for rheumatoid arthritisDaniel E Furst
Pageof 76

Showing results (11-20 of 755) with videos related to

Sort By:
Pageof 76
Seminars in Arthritis and Rheumatism|July 16, 2008
Serum immunoglobulins and risk of infection: how low can you go?Daniel E Furst
Arthritis and Rheumatism|January 1, 1994
Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugsD E Furst
Clinical and Experimental Rheumatology|May 1, 1997
From disease modification to disease control in rheumatoid arthritisD E Furst
Current Opinion in Rheumatology|May 6, 1998
Update on clinical trials in the rheumatic diseasesD E Furst
British Journal of Rheumatology|December 24, 1997
The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseasesD E Furst
The American Journal of Medicine|January 11, 2000
Pharmacology and efficacy of cyclooxygenase (COX) inhibitorsD E Furst
Clinical and Experimental Rheumatology|March 20, 1999
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritisD E Furst
Seminars in Arthritis and Rheumatism|October 1, 1993
Comparing the strengths and weaknesses of observational and experimental studies using a postmarketing surveillance study as a protypic exampleD E Furst
Lupus|June 1, 1996
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseasesD E Furst
Seminars in Arthritis and Rheumatism|January 2, 2009
The risk of infections with biologic therapies for rheumatoid arthritisDaniel E Furst
Pageof 76